Lifeboat Foundation

Dismantling the idea that older generations should ‘step down’ for younger ones.

Humans are really pros at sugarcoating. If you say old people should step down for the sake of new generations, it sounds so noble and rightful, doesn’t it? What it actually means, though, is ‘We value old people less than new ones,’ and this doesn’t sound very noble or rightful. This is plain and brutal survival of the species.

Continue reading “Old generations should step down in favour of the new ones” »

Everolimus heading for human clinical trials later this year to treat immune system decline.

The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis.

PureTech have recently announced a joint venture with Novartis called resTORbio and are moving to clinical trials of the new drugs later this year. The aim of the first test phase is to see if the new drug can rejuvenate the immune system of aged people a key reason why we lose the ability to resist diseases as we grow older.

Continue reading “New drug aimed at slowing aging heads to the clinic” »

For people in that area, and it may be worth while to try reaching out to them for funding for anti aging stuff.

Why is RAND opening a Bay Area office?

The San Francisco Bay Area is really at the center of technology and transformation. That’s also been a focus at RAND since our very first report, Preliminary Design of an Experimental World-Circling Spaceship, in 1946, which foretold the creation of satellites more than a decade before Sputnik.

Continue reading “Innovation in the Bay Area: Q&A with Nidhi Kalra” »

I enjoy meeting authors to discuss their ideas and I met Jim Mellon at the Master Investor show and purchased his book called Fast Forward: The.

The first step in producing an artificial thymus which has potential for cancer age related immune decline.

UCLA researchers have created a new system to produce human T cells, the white blood cells that fight against disease-causing intruders in the body. The system could be utilized to engineer T cells to find and attack cancer cells, which means it could be an important step toward generating a readily available supply of T cells for treating many different types of cancer.

The preclinical study, published in the journal Nature Methods, was led by senior authors Dr. Gay Crooks, a professor of pathology and laboratory medicine and of pediatrics and co-director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and Amelie Montel-Hagen, an associate project scientist in Crooks’ lab.

Continue reading “Artificial thymus can produce cancer-fighting T cells from blood stem cells” »

Interview with George Church.

Harvard researcher Dr. George Church has developed an innovative gene editing technology called CRISPR/Cas9 that could transform senescent cells. He predicts this technology may reverse aging in humans. Life Extension Foundation® assisted by providing Dr. Church with gene sequencing data from its super-centenarian project.

Here’s my speech topic at Moogfest on the Immortality Bus and #transhumanism on May 20 at 4:30PM:

View more about this event at Moogfest 2017.

Another exclusive interview with a hero of gerontology.

Dr. Joao Pedro de Magalhaes talks about aging research in this exclusive interview with LEAF.

Interest in rejuvenation biotechnology is growing in the investment quarter.

Mainstream interest in rejuvenation biotechnology is growing.

“Investment in the development of rejuvenation therapies represents an enormous opportunity for profit; these are products for which every adult human being much over the age of 30 is a potential customer at some price point. That is larger than near every existing industry, either within or outside the field of medicine, even given that customers will only purchase such a therapy once every few years, for clearance of metabolic waste, or even just once, for treatments like the SENS approach of allotopic expression of mitochondrial genes. Among the first successful companies in this space, some will grow to become among the largest in the world: I’d wager that the Ford or Microsoft of rejuvenation will be a lot larger than the actual Ford of automobiles or Microsoft of personal computing.”

Continue reading “Investment Strategist Jim Mellon Considers the Near Future of Longevity Science” »